Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients

Simple Summary A multispecialty discussion may represent a benefit for cancer patients in receiving the most updated pathway of cure. The aim of this study was to describe the activity of our multidisciplinary team (MDT) meeting on patients with colorectal liver metastases (CRLMs). Information about 847 consecutive CRLMs patients over an 11-year period was retrospectively collected. Their characteristics were analyzed, and the populations were compared based on received treatment. There is still debate over how reviewing oncological histories and addressing appropriate therapies in multidisciplinary team (MDT) discussions may affect patients' overall survival (OS). The aim of this study was to describe MDT outcomes for a single cancer center's patients affected by colorectal liver metastases (CRLMs). From 2010 to 2020, a total of 847 patients with CRLMs were discussed at our weekly MDT meeting. Patients' characteristics and MDT decisions were analyzed in two groups: patients receiving systemic therapy (ST) versus patients receiving locoregional treatment (LRT). Propensity-score matching (PSM) was run to reduce the risk of selection bias. The median time from MDT indication to treatment was 27 (IQR 13-51) days. The median OS was 30 (95%CI = 27-34) months. After PSM, OS for patients undergoing LRT was 51 (95%CI = 36-64) months compared with 15 (95%CI = 13-20) months for ST patients (p < 0.0001). In this large retrospective study, the MDT discussions were useful in providing the patients with all available locoregional options.